LIVE

INSP

Inspire Medical Systems, Inc.

INSP

NYSE·Healthcare·Medical - Devices·Mkt cap $1.3B

$46.95

▲ +3.28%

View full research view

Our plain-language verdict, the thesis, risk factors, and what is changing about the business.

View research view

52-Week Range

$38.91 - $147.03

P/E

10.36

Fwd P/E

37.04

Beta

0.73

Div Yield

0.00%

Avg Vol

1.2M

Shares Out

28.8M

Mkt Cap

$1.3B

Price action

Price chart

Down 65.2% over the trailing year

1W
1M
3M
6M
YTD
1Y
5Y
MAX

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

▲

Bull Case

4 reasons

  • Proprietary neurostimulation technology with strong clinical validation
  • FDA approval and market leadership in hypoglossal nerve stimulation
  • High patient compliance and satisfaction rates versus alternative therapies
  • Expanding reimbursement coverage and growing physician network
▼

Bear Case

2 risks

  • Low volatility (beta 0.7).
  • High premium - requires strong execution

Growth

Stable outlook

Increasing diagnosis and treatment rates in OSA patient population

Value

High premium - requires strong execution

Momentum

Weak

-17.3% over 3m

Quality

Excellent

Excellent business quality

Dividend

None

No dividend

Earnings track record

Latest print - beat on both lines

AI-summarized recap of last quarter, plus the surprise on every print.

Next: Aug 3, 2026

“
Q2 26 RECAP

MAY 4, 2026

Reported EPS of $0.10 vs -$0.28 consensus (+136.3% surprise). Revenue of $204.6M vs $200.0M expected (+2.3%). Beat on both top and bottom lines.

EPS beat +136.3%
Rev beat +2.3%
Double beat

EPS surprise · last 4Q

1 of 1 beats

Q2 26

+136.3%

Next: Aug 3, 2026

Revenue trend · last 8Q

—

—

—

+23%

+11%

+10%

+12%

+2%

Q2 24

Q3 24

Q4 24

Q1 25

Q2 25

Q3 25

Q4 25

Q1 26

$195.9M

$203.2M

$239.7M

$201.3M

$217.1M

$224.5M

$269.1M

$204.6M

Margins · last 8Q

Gross

—

Operating

—

Profit

-5.5%

View full earnings history →

Wall Street consensus

12 analysts · 33% Buy

Live ratings and price targets aggregated across covering analysts.

Buy

4

33%

Hold

8

67%

Sell

0%

Median Price Target

$55.00

▲ +17.1% vs $46.95

Low $39.00
Median $55.00
High $70.00

Latest: Oppenheimer · Jun 15, 2026

8 analysts covering

View full analyst page →

vs Industry

How INSP stacks vs Medical - Devices

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.